PCAC Vote Results: FDA Panel Backs 6 of 7 Peptides for Compounding

Meeting overview

The FDA announced in April 2026 that the Pharmacy Compounding Advisory Committee (PCAC) would convene on July 23-24 to evaluate seven peptide nominations for the 503A bulks list. The meeting will be held at FDA's White Oak Campus in Silver Spring, Maryland, with virtual attendance options. The committee will hear nominator presentations, accept comments through open public hearing sessions, deliberate on the evidence, and vote a recommendation to FDA.

The PCAC vote is advisory, not binding. After the meeting, the FDA reviews the recommendation and decides whether to initiate rulemaking to formally add a substance to the 503A bulks list. Even a unanimous positive vote on July 24 does not legalize compounding immediately. Rulemaking typically takes six to twelve months. Negative votes generally end the current nomination, though substances can be re-nominated in future cycles.

Day 1 vote results (July 23)

Each substance got an FDA scientific presentation, nominator and open-public-hearing testimony, then a recorded committee vote. Here is how Day 1 broke down.

The votes recommend adding each peptide (free base and acetate forms) to the Section 503A Bulks List, which governs what licensed pharmacies may compound for individual patients holding a prescription. A recommendation is not FDA approval, and it does not certify that any of these peptides works. Reuters reported that eight of the 14 panel members were appointed under HHS Secretary Robert F. Kennedy Jr., and that several run or work for clinics that offer peptide treatments, a conflict-of-interest point critics raised repeatedly during the meeting.

The advisory panel reshuffle

The makeup of the committee itself has become part of the story. Earlier versions of PCAC were dominated by academic pharmacologists from universities including Duke, Harvard, and Johns Hopkins, and those panels repeatedly voted against adding peptide ingredients to compounding lists. Under HHS Secretary Robert F. Kennedy Jr., the panel weighing these seven peptides has been reshaped to include practitioners who run peptide clinics, sell peptide injections, or promote the substances publicly. That creates a direct tension: FDA staff on record against the peptides, a panel weighted toward access, and a final decision that still rests with the agency after the vote.

For patients and prescribers, the practical read is that the outcome is less predictable than a normal PCAC cycle. A panel sympathetic to compounding access could vote to recommend one or more peptides over staff objections. FDA leadership would then decide whether to follow the panel or its own reviewers. Either path still runs through months of rulemaking before anything changes at the pharmacy counter.

Day-by-day schedule

BPC-157: the highest-profile nomination

BPC-157 is the most widely used peptide on the July 23 schedule. The nomination is specifically for ulcerative colitis, a narrower indication than the broader gut-healing use cases the peptide is associated with in the wellness market. The committee will evaluate whether the available clinical and preclinical evidence supports the safety and effectiveness of compounded BPC-157 for ulcerative colitis. Most of the existing literature is preclinical and rodent-model based, with limited controlled human data, though case series and observational reports exist.

A favorable PCAC recommendation does not legalize BPC-157 for general use. It would create a pathway specifically for ulcerative colitis prescriptions through compounding pharmacies. Off-label use would still be possible but would expose prescribers to greater scrutiny. See our guides on BPC-157 for gut healing, BPC-157 dosage, and BPC-157 side effects for the existing clinical picture. For where the peptide stands right now, see BPC-157 FDA status in 2026.

KPV: short tripeptide with the strongest evidence base

KPV (lysine-proline-valine) is a tripeptide derived from alpha-melanocyte stimulating hormone. It has a relatively narrow molecular profile, a clean preclinical safety record, and meaningful published literature for inflammatory bowel disease and inflammatory skin conditions. The nomination for wound healing and inflammatory conditions is broader than the strongest evidence base supports, which may complicate the vote.

KPV is one of the two peptides on the July 23 schedule with the most plausible path to a favorable recommendation, alongside BPC-157. See our coverage on KPV for gut health, KPV benefits, and KPV dosage.

TB-500: long compounding history, mixed evidence

TB-500 (a synthetic fragment of thymosin beta-4) has a long history in the peptide compounding market for soft-tissue repair. The clinical evidence in humans is weaker than BPC-157 or KPV, leaning heavily on preclinical models and athlete anecdote. The nominated use is wound healing, which may stretch the evidence beyond what controlled studies support.

The committee may struggle with the gap between widespread compounding use and limited rigorous evidence. A negative vote here would not be surprising. See our guides on TB-500 dosage, BPC-157 vs TB-500, and the BPC-157 + TB-500 blend for clinical context.

MOTS-c: novel mitochondrial peptide, thin clinical data

MOTS-c is a mitochondrial-derived peptide with active preclinical research for metabolic disease and aging. The nominated uses, obesity and osteoporosis, both have indirect evidence from animal models but limited controlled human trials. The committee will likely flag the evidence gap.

MOTS-c sits in the early-stage research category where compounding approval is harder to justify without more human safety and efficacy data. See our MOTS-c peptide overview and MOTS-c dosage for the current state of the literature.

Day 2: emideltide (DSIP), Semax, Epitalon

The Day 2 votes were recorded July 24, 2026. The committee recommended two of the three substances and rejected one.

The July 24 substances all have decades of use, mostly in Eastern European and Russian medical practice, but limited Western controlled trial data. Emideltide (DSIP) was the one nomination the access-leaning panel could not carry: its 6-7 rejection suggests the thin human evidence for opioid withdrawal and narcolepsy outweighed the committee's general willingness to expand access. Semax and Epitalon cleared despite similar evidence-quality concerns, tracking the Day 1 pattern where the reshaped committee backed nominations over FDA staff objections.

• DSIP (delta sleep-inducing peptide, emideltide): The uses FDA evaluated are opioid withdrawal, chronic insomnia, and narcolepsy. Mechanism is plausible but human RCT data is thin. See our DSIP peptide guide.
• Semax: The uses FDA evaluated are cerebral ischemia, migraine, and trigeminal neuralgia; the peptide is better known in the wellness market for cognitive enhancement. US-language clinical data is limited. See Semax peptide and Semax vs Selank.
• Epitalon: The use FDA evaluated is insomnia, though the peptide is marketed for longevity. Those longevity claims rely on aging cohort studies from a single research group, which is a structural evidence weakness. See Epitalon benefits.

How to submit a public comment

Each substance has its own docket. To submit comment:

1. Go to regulations.gov and open docket FDA-2025-N-6895, the docket for the July 23-24, 2026 PCAC meeting.
2. Deadline: the July 9, 2026 cutoff to have comments formally distributed to committee members has passed. The docket stays open for the record through July 22, 2026; comments filed now still enter the public record but arrive after members already have their briefing packages.
3. Submit comment to the relevant peptide docket. Comments addressed to the general PCAC docket are less effective.
4. Specific clinical case material, peer-reviewed evidence, and detailed safety data carry more weight than general expressions of support.
5. If you want to speak during the open public hearing, sign up in advance through the meeting registration link in the Federal Register notice. Slots are limited.

What to watch on the day

Three signals to track during the meeting:

• Committee composition: PCAC members rotate. The clinical pharmacology and compounding pharmacy members tend to be more sympathetic to compounding access. Industry representatives and FDA staff tend to apply stricter evidence criteria.
• Nominator presentations: The strength of the case made by each nominator predicts the vote more than any other variable. Well-prepared nominators with detailed clinical evidence outperform weaker presentations regardless of peptide popularity.
• Tie votes and abstentions: A close vote with multiple abstentions usually signals the FDA will request additional information rather than rule definitively.

Related regulatory actions

The PCAC hearing is one of three concurrent peptide regulatory threads:

• The April 2025 reclassification of 14 peptides from Category 2 to Category 1. See which 14 peptides are legal again in 2026.
• The May 2026 FDA proposed rule excluding semaglutide, tirzepatide, and liraglutide from the 503B bulks list. See FDA 503B GLP-1 exclusion.
• The ongoing FDA enforcement against research peptide vendors marketing for human use. See FDA peptide ban.
• Peptides that were not nominated stay exactly where they are, regardless of how this vote goes. Kisspeptin is a useful example: a well-characterized peptide with a real clinical trial program that is not on any bulks-list pathway and has no scheduled review.

Does this open a dietary supplement pathway?

It does not, and the two questions are being conflated constantly in coverage of the vote. The 503A bulks list governs what a licensed compounding pharmacy may prepare against an individual prescription. The dietary supplement pathway is a separate statutory track under DSHEA with its own test: the substance has to qualify as a dietary ingredient, be reasonably expected to be safe, and in most cases clear a New Dietary Ingredient Notification filed with FDA at least 75 days before marketing.

Supplement-industry groups did press the broader question at the meeting's margins, arguing for a wider reading of what counts as a dietary ingredient so that peptides could be formulated into supplements. Nothing at the July 23-24 hearing resolved it. The harder barrier for BPC-157 and similar sequences is the drug-preclusion clause: once a substance has been authorized for investigation as a new drug and that investigation is public, it generally cannot be introduced as a dietary ingredient afterward.

The practical consequence is that a peptide placed on the 503A list becomes more firmly a prescription drug, not a retail product. If you want a leading indicator for the supplement question, watch for New Dietary Ingredient Notifications on specific peptides, not compounding votes. We cover the distinction in peptide supplements: what is actually legal to buy, and the absorption problem that limits oral formats regardless of legal status in oral peptides.

Bottom line

The July 23-24 hearing was the most significant peptide regulatory event of 2026 on the access side, and it broke toward access: the panel recommended six of seven peptides over the objections of FDA career scientists, rejecting only emideltide (DSIP). That is a meaningful signal for the tens of thousands of patients currently buying research-grade peptides through the gray market, but it changes nothing today. Three separate legal events keep getting collapsed into one: removal from Category 2, a PCAC recommendation, and actual placement on the compoundable list after notice-and-comment rulemaking. The vote only cleared the second of those, and only as a recommendation the FDA can still reject. Realistic timelines for a legal 503A compounding pathway run eight to twelve months at minimum, into 2027. Until then, anything sold as BPC-157, KPV, TB-500, MOTS-c, Semax, or Epitalon remains an unapproved research chemical with no FDA oversight of purity or dosing.

Sources

• FDA: July 23-24, 2026 Meeting of the PCAC
• NPR: FDA scientists flag concerns with peptides ahead of the July panel
• AJMC: FDA to Convene Expert Panel on Expanding Access to Peptides
• Lengea Law: FDA Puts BPC-157, TB-500, and Five Other Peptides Under the Microscope
• Loti Labs: FDA Peptide Regulations 2026
• Fortune: The FDA peptide vote could create telehealth's next market (July 20, 2026)
• Forbes: FDA's Review of Peptides Signals a Growing Public Health Challenge (July 21, 2026)
• NutraIngredients: FDA peptide panel raises questions about future dietary supplement pathway (July 27, 2026)
• Washington Post: FDA raised conflict-of-interest concerns ahead of the new peptide panel (July 17, 2026)